Compare · RGNX vs SRPT
RGNX vs SRPT
Side-by-side comparison of REGENXBIO Inc. (RGNX) and Sarepta Therapeutics Inc. (SRPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while SRPT focuses on Biotechnology: Pharmaceutical Preparations.
- SRPT is the larger of the two at $1.43B, about 3.0x RGNX ($473.4M).
- RGNX has been more active in the news (9 items in the past 4 weeks vs 7 for SRPT).
- SRPT has more recent analyst coverage (25 ratings vs 24 for RGNX).
- Company
- REGENXBIO Inc.
- Sarepta Therapeutics Inc.
- Price
- -
- -
- Market cap
- $473.4M
- $1.43B
- 1M return
- -
- -26.57%
- 1Y return
- -
- -29.52%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 9
- 7
- Recent ratings
- 24
- 25
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Latest RGNX
- SEC Form SCHEDULE 13G filed by REGENXBIO Inc.
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
- Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)
- Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)
- REGENXBIO to Participate in Stifel 2026 Healthcare Conference
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
Latest SRPT
- SEC Form 13F-HR filed by Sarepta Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics upgraded by Deutsche Bank with a new price target
- Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
- SEC Form 10-Q filed by Sarepta Therapeutics Inc.
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting